Floatz logo

Realgar-Indigo Naturalis Formulation

Platinum-resistant Ovarian Cancer (PROC)

Peking University People's HospitalPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

524 Active assets in the Platinum-resistant Ovarian Cancer (PROC) cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Kalinski, Pawel, MD, PhD
Phase 3BB
Inno-206
Genmab
Phase 3BB

View all 50 →

Same molecule, other indications

Realgar-Indigo Naturalis Formulation is also rated in:

acute promyelocytic leukemiaDormant
BB
Indicative ·
66 / 100
View asset →
Arsenic TrioxideDormant
BB
Indicative ·
65 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →